

September 1, 2020

Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Dainippon Pharma Announces Organizational Realignment and Change in Executive Officer

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) today announced the following organizational realignment and change in Executive Officer, effective October 1, 2020:

I. Organizational Realignment (effective October 1, 2020)

Sales & Marketing (Division)

CNS Sales Department is created and Psychiatry Groups belonging to Branches are transferred to CNS Sales Department.*

- * By improving the efficiency of information sharing as well as instruction transmission, and also by developing a unified strategy, we will strengthen the organization toward becoming a leading pharmaceutical company in Psychiatry & Neurology area in Japan.

II. Change in Executive Officer

Change in the position assumed by Executive Officer (effective October 1, 2020)

Position as of October 1, 2020	Current position	Name
Member, Board of Directors, Executive Vice President Executive Director, Sales & Marketing Division Senior Director, CNS Sales Department Head of Japan Business Unit	Member, Board of Directors, Executive Vice President Executive Director, Sales & Marketing Division Head of Japan Business Unit	Hitoshi Odagiri

Contact:

Corporate Communications

Sumitomo Dainippon Pharma Co., Ltd.

TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)